NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
+$0.05 today
- Market cap
- $283.19M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
Volume 0.31M
Average 0.18M
NPCE Interest Income
Income earned on cash, deposits, and investments held by the company.
NeuroPace, Inc.NASDAQ: NPCE
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $565K fell 28.8% year over year, behind the -13.4% change in trailing-twelve-month interest income. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.
Context
- Interest income amounted to 2.8% of revenue in FY2025, down 1.0 pp from a year earlier.
- Interest income increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -28.8% toward the trailing-twelve-month pace of -13.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 2.82M USD
- Year-over-year change
- -6.9%
- 4-year CAGR
- +58.3%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.82M | -6.9% |
| FY2024 | 2024-12-31 | 3.02M | -0.9% |
| FY2023 | 2023-12-31 | 3.05M | +93.3% |
| FY2022 | 2022-12-31 | 1.58M | +252.2% |
| FY2021 | 2021-12-31 | 448K | — |
Interest Income vs competitors
How NPCE compares with its peers on the latest reported figures
- NPCE's LTM Mar 2026 interest income of $2.59M is the highest of the 2 companies compared; the peer median is $0.
- Interest income amounts to 2.6% of revenue for NPCE, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.59M | -13.4% | +21.3% | 2.6% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding NPCE) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.18M | 45.52M | 65.42M | 79.91M | 99.99M |
| Cost of Revenue | 11.75M | 13.03M | 17.3M | 20.82M | 22.77M |
| Gross Profit | 33.44M | 32.49M | 48.12M | 59.09M | 77.22M |
| Gross Margin | 74.0% | 71.4% | 73.6% | 73.9% | 77.2% |
| Research & Development | 18.21M | 21.95M | 20.78M | 23.65M | 27.89M |
| Selling, General & Admin | 38.96M | 51.34M | 54.52M | 57.1M | 65.67M |
| Operating Expenses | 57.17M | 73.29M | 75.3M | 80.76M | 93.56M |
| Depreciation & Amortization | 296K | 2.99M | 1.61M | 1.77M | 1.95M |
| EBITDA | (28.37M) | (36.57M) | (22.83M) | (16.57M) | (12.06M) |
| EBITDA Margin | -62.8% | -80.3% | -34.9% | -20.7% | -12.1% |
| Operating Income | (23.74M) | (40.79M) | (27.17M) | (21.67M) | (16.34M) |
| Operating Margin | -52.5% | -89.6% | -41.5% | -27.1% | -16.3% |
| Interest Income | 448K | 1.58M | 3.05M | 3.02M | 2.82M |
| Interest Expense | 7.41M | 7.53M | 8.52M | 8.8M | 7.46M |
| Other Income / Expenses | (12.34M) | (6.29M) | (5.78M) | (5.47M) | (5.13M) |
| Income Before Tax | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Pre-Tax Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Net Margin | -79.9% | -103.4% | -50.4% | -34.0% | -21.5% |
| EPS (Basic) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| EPS (Diluted) | (2.17) | (1.91) | (1.27) | (0.93) | (0.66) |
| Weighted Avg Shares | 16.61M | 24.59M | 25.85M | 29.13M | 32.72M |
| Weighted Avg Shares (Diluted) | 16.61M | 24.59M | 25.85M | 29.13M | 32.72M |
NeuroPace, Inc.
NASDAQ:NPCE
Intrinsic Alpha fair value
Locked
Current Price
$8.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.